CAMBRIDGE, Mass., May 16, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today it will host a conference call and webcast to provide a business update on May 21, 2019 at 4:30 pm ET. Live and archived versions of the event can be accessed via the Company’s website.
Members of the Cue Biopharma executive management team will provide an update on the Company’s platform and pipeline progress, as well as updates on its strategic objectives and anticipated milestones.
To access the webcast, visit the Events and Webcasts page within the Investor Relations section of the Company’s website at www.cuebio.com. Please log on at least 15 minutes before the conference call to allow adequate time should any software download or browser update be required to listen to the webcast. To join by phone, please call 866-679-9651 (domestic) or 409-231-2082 (international) and provide the conference call passcode 4064108.
A telephone replay will be available until 7:30 pm ET on May 28, 2019. Access numbers for the telephone replay are: 855-859-2056 (domestic) and 404-537-3406 (international); the passcode is 4064108. A webcast replay will also be archived on http://www.cuebio.com for 45 days.
About Cue Biopharma
Cue Biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers, autoimmune and chronic infectious diseases. We design biologics to engage and modulate the activity of disease-associated T cells in the patient’s body, with the goal of offering significant therapeutic benefits while potentially minimizing or eliminating unwanted side effects.
We believe our selective biologics allow us to target antigen-specific T cell populations in a variety of indications using a peptide – MHC complex for delivering T cell modulating effectors, such as IL-2. Once a biologic has been optimized, our approach offers the potential for readily exchanging peptides to target different T cell populations and indications using previously-validated drug frameworks developed from the Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform. This flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost-efficiently than current industry standards.
Headquartered in Cambridge, MA, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.
For more information, visit www.cuebio.com.
Investor Contact:
John Woolford
Westwicke
443-213-0506
Media Contact:
Mike Beyer
Sam Brown Inc.
312-961-2502
Source: Cue Biopharma, Inc.
Source: Cue Biopharma, Inc.